{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:21:09Z","timestamp":1694989269772},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T00:00:00Z","timestamp":1307059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12032-011-9995-8","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T06:44:50Z","timestamp":1307083490000},"page":"1468-1476","source":"Crossref","is-referenced-by-count":4,"title":["Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system"],"prefix":"10.1007","volume":"29","author":[{"given":"Henriqueta Coimbra","family":"Silva","sequence":"first","affiliation":[]},{"given":"Vera","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Luis Alcides Mesquita","family":"Nogueira","sequence":"additional","affiliation":[]},{"given":"Manuel Santos","family":"Rosa","sequence":"additional","affiliation":[]},{"given":"Lina","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Regateiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,6,3]]},"reference":[{"key":"9995_CR1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jcp.55.6.429","volume":"55","author":"C Costa","year":"2002","unstructured":"Costa C, Soares R, Reis-Filho JS. Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55:429\u201334.","journal-title":"J Clin Pathol"},{"key":"9995_CR2","first-page":"632","volume":"62","author":"A Ristim\u00e4ki","year":"2002","unstructured":"Ristim\u00e4ki A, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632\u20135.","journal-title":"Cancer Res"},{"key":"9995_CR3","first-page":"1393","volume":"26","author":"B Singh","year":"2005","unstructured":"Singh B, Berry JA, Sholer A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005;26:1393\u20139.","journal-title":"Int J Oncol"},{"key":"9995_CR4","first-page":"1306","volume":"60","author":"JL Masferrer","year":"2000","unstructured":"Masferrer JL, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306\u201311.","journal-title":"Cancer Res"},{"key":"9995_CR5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bjc.6600462","volume":"87","author":"EM Connolly","year":"2002","unstructured":"Connolly EM, et al. Cyclooxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer. 2002;87:231\u20137.","journal-title":"Br J Cancer"},{"key":"9995_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2407-6-181","volume":"6","author":"TL Larkins","year":"2006","unstructured":"Larkins TL, Nowell M, Singh S, Sanford G. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006;6:181\u201392.","journal-title":"BMC Cancer"},{"key":"9995_CR7","doi-asserted-by":"crossref","unstructured":"Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast. 2011. doi: 10.1016\/j.breast.2010.07.004 .","DOI":"10.1016\/j.breast.2010.07.004"},{"key":"9995_CR8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873\u201384.","journal-title":"N Engl J Med"},{"key":"9995_CR9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","volume":"38","author":"JR Vane","year":"1998","unstructured":"Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97\u2013120.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9995_CR10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.bjc.6601534","volume":"90","author":"GP Boland","year":"2004","unstructured":"Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 2004;90:423\u20139.","journal-title":"Br J Cancer"},{"key":"9995_CR11","doi-asserted-by":"crossref","first-page":"18563","DOI":"10.1074\/jbc.M010787200","volume":"276","author":"CH Liu","year":"2001","unstructured":"Liu CH, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001;276:18563\u20139.","journal-title":"J Biol Chem"},{"issue":"6824","key":"9995_CR12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A M\u00fcller","year":"2001","unstructured":"M\u00fcller A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50\u20136.","journal-title":"Nature"},{"key":"9995_CR13","doi-asserted-by":"crossref","unstructured":"Rhodes LV et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2010. doi: 10.1158\/0008-5472.CAN-10-3185 .","DOI":"10.1158\/0008-5472.CAN-10-3185"},{"key":"9995_CR14","first-page":"5736","volume":"61","author":"RE Bachelder","year":"2001","unstructured":"Bachelder RE, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61:5736\u201340.","journal-title":"Cancer Res"},{"key":"9995_CR15","first-page":"7203","volume":"62","author":"RE Bachelder","year":"2002","unstructured":"Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002;62:7203\u20136.","journal-title":"Cancer Res"},{"key":"9995_CR16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/sj.bjc.6602308","volume":"92","author":"MP Barr","year":"2005","unstructured":"Barr MP, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer. 2005;92:328\u201333.","journal-title":"Br J Cancer"},{"key":"9995_CR17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1054\/bjoc.2001.1876","volume":"85","author":"GP Pidgeon","year":"2001","unstructured":"Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates Bcl-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer. 2001;85:273\u20138.","journal-title":"Br J Cancer"},{"key":"9995_CR18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0006-291X(03)01079-9","volume":"306","author":"G Eibl","year":"2003","unstructured":"Eibl G, et al. PGE2 is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 2003;306:887\u201397.","journal-title":"Biochem Biophys Res Commun"},{"key":"9995_CR19","doi-asserted-by":"crossref","first-page":"R422","DOI":"10.1186\/bcr1019","volume":"7","author":"GD Basu","year":"2005","unstructured":"Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005;7:R422\u201335.","journal-title":"Breast Cancer Res"},{"key":"9995_CR20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clinbiochem.2004.05.013","volume":"37","author":"MJ Duffy","year":"2004","unstructured":"Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem. 2004;37:541\u20138.","journal-title":"Clin Biochem"},{"key":"9995_CR21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/clinchem\/44.6.1177","volume":"44","author":"MJ Duffy","year":"1998","unstructured":"Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O\u2019Higgins NJ. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem. 1998;44:1177\u201383.","journal-title":"Clin Chem"},{"key":"9995_CR22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/94.2.116","volume":"94","author":"MP Look","year":"2002","unstructured":"Look MP, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116\u201328.","journal-title":"J Natl Cancer Inst"},{"key":"9995_CR23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0006-291X(02)02707-9","volume":"299","author":"G Li","year":"2002","unstructured":"Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumour cells. Biochem Biophys Res Commmun. 2002;299:886\u201390.","journal-title":"Biochem Biophys Res Commmun"},{"key":"9995_CR24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s10350-007-9120-4","volume":"51","author":"E Leung","year":"2007","unstructured":"Leung E, McArthur D, Morris A, Williams N. Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression. Dis Colon Rectum. 2007;51:342\u20137.","journal-title":"Dis Colon Rectum"},{"key":"9995_CR25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-004-0714-4","volume":"89","author":"A Sivula","year":"2005","unstructured":"Sivula A, et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 2005;89:215\u201320.","journal-title":"Breast Cancer Res Treat"},{"key":"9995_CR26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0090-8258(03)00084-2","volume":"88","author":"AR Munkarah","year":"2003","unstructured":"Munkarah AR, et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol. 2003;88:429\u201333.","journal-title":"Gynecol Oncol"},{"key":"9995_CR27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.bjc.6603593","volume":"96","author":"NL Barnes","year":"2007","unstructured":"Barnes NL, et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer. 2007;96:575\u201382.","journal-title":"Br J Cancer"},{"key":"9995_CR28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ijc.1376","volume":"93","author":"JG Rozic","year":"2001","unstructured":"Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 2001;93:497\u2013506.","journal-title":"Int J Cancer"},{"key":"9995_CR29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-4827(03)00269-6","volume":"289","author":"A Timoshenko","year":"2003","unstructured":"Timoshenko A, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandine E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res. 2003;289:265\u201374.","journal-title":"Exp Cell Res"},{"key":"9995_CR30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/0008-5472.967.65.3","volume":"65","author":"Z Liang","year":"2005","unstructured":"Liang Z, et al. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65:967\u201371.","journal-title":"Cancer Res"},{"key":"9995_CR31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.4049\/jimmunol.162.3.1392","volume":"162","author":"SW Cole","year":"1999","unstructured":"Cole SW, Jamieson BD, Zack JA. cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection. J Immunol. 1999;162:1392\u2013400.","journal-title":"J Immunol"},{"key":"9995_CR32","doi-asserted-by":"crossref","first-page":"35451","DOI":"10.1074\/jbc.M302474200","volume":"278","author":"FG Buchanan","year":"2003","unstructured":"Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278:35451\u20137.","journal-title":"J Biol Chem"},{"key":"9995_CR33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djj206","volume":"98","author":"S Gr\u00f6sch","year":"2006","unstructured":"Gr\u00f6sch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98:736\u201347.","journal-title":"J Natl Cancer Inst"},{"key":"9995_CR34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-008-0229-5","volume":"116","author":"C Falandry","year":"2009","unstructured":"Falandry C, et al. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat. 2009;116:501\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"9995_CR35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-010-0939-3","volume":"122","author":"J-Y Pierga","year":"2010","unstructured":"Pierga J-Y, et al. A multicenter randomized phase II study of sequential epirubicin\/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat. 2010;122:429\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"9995_CR36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsbmb.2007.05.021","volume":"106","author":"RW Brueggemeier","year":"2007","unstructured":"Brueggemeier RW, Su B, Sugimoto Y, D\u00edaz-Cruz ES, Davis DD. Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol. 2007;106:16\u201323.","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-9995-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-9995-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-9995-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T05:19:14Z","timestamp":1686115154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-9995-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["9995"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-9995-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,3]]}}}